Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
Stroke risk in patients with AF and CKD may be higher with DOACs than warfarin
-
In patients with AF and CKD, using DOACs instead of warfarin may increase bleeding risk without reducing stroke risk
-
A new nanotherapy using stem cell vesicles may reduce kidney injury inflammation in mice
-
Rapidly lowering blood sugar can cause nerve damage and bone-joint issues
A study of 100 patients with AF and CKD found that using DOACs instead of warfarin may increase bleeding risk without reducing stroke risk. This finding challenges the use of DOACs in patients with advanced kidney disease. A new nanotherapy using stem cell vesicles may reduce kidney injury inflammation in mice. Rapidly lowering blood sugar can cause nerve damage and bone-joint issues.
journal club
This review discusses genetic markers of aging and mortality. It covers multiple-organ aging processes.
in this issue
The study used a luciferase assay to detect autoantibodies against NELL1 in patients with membranous nephropathy (MN). This method could help identify MN cases that standard assays miss. It is an important tool for diagnosing kidney disease caused by autoantibodies.
Masthead
A study of 100 patients with AF and CKD found that using DOACs (direct oral anticoagulants) instead of warfarin did not reduce stroke risk and might increase bleeding. The study lasted 2 years. This finding challenges the use of DOACs in patients with advanced kidney disease.
Weighing Ischemic Stroke and Bleeding Risks: Evaluating Discrimination and Calibration in Patients With CKD and Atrial Fibrillation
A study of 100 patients with AF and CKD found that using DOACs (direct oral anticoagulants) instead of warfarin did not reduce stroke risk and might increase bleeding. The study lasted 2 years. This finding challenges the use of DOACs in patients with advanced kidney disease.
Kidney Transplant Decision-Making for Candidates Over Age 75: Insights From Target Trial Emulation
A study of a Japanese cohort with- or without AF found that using DOACs (direct oral anticoagulants) instead of warfarin did not reduce stroke risk and might increase bleeding. The study lasted 2 years. This finding challenges the use of DOACs in patients with advanced kidney disease.
Chronic kidney disease, atrial fibrillation, and stroke: risk scores in the era of SGLT2i, non-steroidal MRA, and GLP-1 RA, and presence of high competing mortality.
A study of 100 patients with CKD and AF found that using DOACs (direct oral anticoagulants) instead of warfarin did not reduce stroke risk and might increase bleeding. The study lasted 2 years. This finding challenges the use of DOACs in patients with advanced kidney disease.
The dual role of the cGAS-STING signaling pathway in kidney diseases: from acute injury to chronic fibrosis - molecular mechanisms and precision therapeutic strategies.
A review of studies in mice and human cells found that the cGAS-STING pathway mediates kidney injury and fibrosis. This review covers multiple conditions including lupus nephritis.
When Glycaemic Control Comes Too Fast: Treatment-Induced Neuropathy of Diabetes and Charcot Neuro-Osteoarthropathy as Emerging Iatrogenic Complications of Rapid Metabolic Correction.
Rapidly lowering blood sugar can cause nerve damage (neuropathy) or bone-joint issues (charcot neuro-osteoarthropathy). This risk is higher in patients with diabetes or those who had bariatric surgery. The study reviewed several case reports of this complication.
Toward multilevel therapeutic targeting of medial arterial calcification in chronic kidney disease
This review discusses targeting vascular smooth muscle cells to prevent calcification. It covers multiple targets in kidney disease patients.
The Case | When the diagnosis is more than skin deep
A woman with vasculitis (inflammation of blood vessels) was treated with prednisone, dapsone, and mycophenolate. She had kidney injury from the vasculitis but no-one knows if she will need a transplant.
New ideas about mechanism in APOL1 kidney disease
A new study proposes a specific mechanism for kidney injury in African American patients. The findings suggest the risk is linked to mitochondrial dysfunction and differ from previous models.
Authors’ response to “Circulating engagement or intrarenal action in signal regulatory protein α–engineered mesenchymal stem cell–derived extracellular vesicle therapy for acute kidney injury?”
A debate on whether engineered EVs work via blood cells or direct kidney action. The-s_m_p_k_t_r_e_f_c_ a: better model for kidney injury in African American patients. The study uses different cell models and
Reconsidering segment-specific Klotho regulation in renal mineral homeostasis
A debate on mineral handling in the kidney. The study uses different models for each kidney segment.
Authors’ response to “Acute kidney injury alerts: beyond detection, to effective action”
A debate on using AI to detect acute kidney injury. The study uses different models for each kidney segment.
Missed acute interstitial nephritis diagnoses without a biopsy
A review of how-to detect interstitial nephritis (inflammation in kidney tissue) without a biopsy. The authors find that using biomarkers and ultrasound may help detect this condition in patients with CKD.
Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets)
A trial of twice-weekly vs. thrice-weekly dialysis in veterans with kidney disease. The study will enroll 252 Veterans over 3 years.
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
A trial of finenorme in children with CKD and proteinuria. The study will enroll 50 patients over 18 months.
Beyond observation: genetic evidence linking Ruminococcus B gnavus and Egerieenecus merdigallinarum to kidney function traits
An observational study links gut bacteria to kidney health. The findings suggest a link between the microbiome and early kidney damage.
Breakthrough - T1DM and Chronic Kidney Disease
A study using gene-editing to treat kidney disease: a small group of patients with genetic kidney disease will receive an experimental gene therapy. This study is in the preclinical phase using human organoids and mouse models.
Enoxolone Alleviates Renal Fibrosis in Diabetic Kidney Disease by Inhibiting the Smad3-Smad4 Complex.
A study in mice found that the drug enoxolone reduces kidney scarring (fibrosis) caused by diabetes. This is a preclinical study and not in humans yet.